<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.0 Transitional//EN"
                      "http://www.w3.org/TR/REC-html40/loose.dtd">
<HTML>
<HEAD>
<TITLE>extropians: ALT-711; New Study</TITLE>
<META NAME="Author" CONTENT="Doug Skrecky (oberon@vcn.bc.ca)">
<META NAME="Subject" CONTENT="ALT-711; New Study">
</HEAD>
<BODY BGCOLOR="#FFFFFF" TEXT="#000000">
<H1>ALT-711; New Study</H1>
<!-- received="Thu Mar 16 09:36:34 2000" -->
<!-- isoreceived="20000316163634" -->
<!-- sent="Thu, 16 Mar 2000 08:36:38 -0800 (PST)" -->
<!-- isosent="20000316163638" -->
<!-- name="Doug Skrecky" -->
<!-- email="oberon@vcn.bc.ca" -->
<!-- subject="ALT-711; New Study" -->
<!-- id="Pine.GSO.4.21.0003160836000.9789-100000@vcn.bc.ca" -->
<STRONG>From:</STRONG> Doug Skrecky (<A HREF="mailto:oberon@vcn.bc.ca?Subject=Re:%20ALT-711;%20New%20Study&In-Reply-To=&lt;Pine.GSO.4.21.0003160836000.9789-100000@vcn.bc.ca&gt;"><EM>oberon@vcn.bc.ca</EM></A>)<BR>
<STRONG>Date:</STRONG> Thu Mar 16 2000 - 09:36:38 MST
<P>
<!-- next="start" -->
<UL>
<LI><STRONG>Next message:</STRONG> <A HREF="5074.html">Brian D Williams: "[GUNS] Re: g*n c*ntr*l"</A>
<LI><STRONG>Previous message:</STRONG> <A HREF="5072.html">James Wetterau: "Re: Patent breakthrough- maybe we don't need them after all?"</A>
<!-- nextthread="start" -->
<!-- reply="end" -->
<LI><STRONG>Messages sorted by:</STRONG> 
<A HREF="date.html#5073">[ date ]</A>
<A HREF="index.html#5073">[ thread ]</A>
<A HREF="subject.html#5073">[ subject ]</A>
<A HREF="author.html#5073">[ author ]</A>
</UL>
<HR NOSHADE><P>
<!-- body="start" -->
<P>
CryoNet - Thu 16 Mar 2000
<BR>
Message #13394
<BR>
From: Olaf Henny
<BR>
<P>&nbsp;RAMSEY, N.J., March 15 /PRNewswire/ -- Alteon Inc. (OTC Bulletin Board: ALTN),
<BR>
announced today that a new pre-clinical study of ALT-711, lead Advanced Glycosylation
<BR>
End-Product (&quot;A.G.E.&quot;) Crosslink Breaker, has been published in the March 14th issue of
<BR>
the Proceedings of the National Academy of Sciences (PNAS). The article details
<BR>
ALT-711's ability to reverse cardiac stiffness in aged dogs, restoring the
<BR>
cardiovascular system to a state found in younger animals.
<BR>
<P>&nbsp;In this study, administration of ALT-711 daily for one month resulted in a 40%
<BR>
reduction in age-related ventricular stiffness, or hardening. This decrease in
<BR>
stiffness was accompanied by an overall improvement in cardiac function, as evidenced
<BR>
by increased left ventricular end-diastolic volume, stroke volume and decreased
<BR>
end-diastolic pressure.
<BR>
<P><!-- body="end" -->
<HR NOSHADE>
<UL>
<!-- next="start" -->
<LI><STRONG>Next message:</STRONG> <A HREF="5074.html">Brian D Williams: "[GUNS] Re: g*n c*ntr*l"</A>
<LI><STRONG>Previous message:</STRONG> <A HREF="5072.html">James Wetterau: "Re: Patent breakthrough- maybe we don't need them after all?"</A>
<!-- nextthread="start" -->
<!-- reply="end" -->
<LI><STRONG>Messages sorted by:</STRONG> 
<A HREF="date.html#5073">[ date ]</A>
<A HREF="index.html#5073">[ thread ]</A>
<A HREF="subject.html#5073">[ subject ]</A>
<A HREF="author.html#5073">[ author ]</A>
</UL>
<!-- trailer="footer" -->
<HR NOSHADE>
<P>
<SMALL>
<EM>
This archive was generated by <A HREF="http://www.hypermail.org/">hypermail 2b29</A> 
: <EM>Thu Jul 27 2000 - 14:05:24 MDT</EM>
</EM>
</SMALL>
</BODY>
</HTML>
